We speculate that the absence of this pretreatment immunosuppression in responders promotes the 1) advantageous spatial interactions of tumor and PD-1+ CD4+ T cells that underlies the lower SpatialScore and 2) priming and activation of CD4+ T cells following immunotherapy. This evidence concerns the gene CD4 and neoplasm.